CRd

Cyclophosphamide

None

An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm's tumor. Alkylating agent

This drug should be coded

Lenalidomide

None

None

May 28, 2019: FDA approved lenalidomide (REVLIMID) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL).


2/22/2017: FDA approved lenalidomide (Revlimid) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.

July 2013 UPDATE: Revlimid received FDA approval for use in the treatment of mantle cell lymphoma (MCL) whose disease has relapsed after two prior therapies, one of which included bortezomib.

FDA approved for MDS 2005, for multiple myeloma 2006, orphan drug status CLL
Thalidomide analog immunomodulatory derivative.

February 20, 2015 update: FDA approved revlimid given in combination with dexamethasone as first course treatment for newly diagnosed multiple myeloma.

This drug should be coded

Dexamethasone

None

None

NOTE* Dexamethasone may be coded as either an ancillary drug or hormone. Review chart to determine if given for supportive care or as hormonal therapy.

A long-acting corticosteroid (glucocorticoid). In general, this drug is used more commonly for supportive care, and as an antiemetic than it is as hormone therapy. 25 times as potent as cortisol; used topically as an anti-inflammatory and administered orally in replacement therapy for adrenal insufficiency, as an anti-inflammatory and immunosuppressant in a wide variety of disorders, and as an antiemetic in cancer chemotherapy. Dexamethasone and other corticosteroids may be used to control white cell proliferation in hematopoietic diseases and would be coded as hormone therapy for leukemia, lymphoma and multiple myeloma.

Please see remarks for additional information